Probi AB (publ) (PROB.ST)

SEK 347.0

(-0.29%)

Market Cap (In SEK)

3.95 Billion

Revenue (In SEK)

627.68 Million

Net Income (In SEK)

16.81 Million

Avg. Volume

577.00

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
181.0-351.0
PE
-
EPS
-
Beta Value
0.464
ISIN
SE0001280355
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Ms. Anita Johansen
Employee Count
-
Website
https://www.probi.com
Ipo Date
2004-12-02
Details
Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.